EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report
- PMID: 29177080
- PMCID: PMC5687535
- DOI: 10.1136/rmdopen-2017-000507
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report
Abstract
Objective: To describe the methodology used to develop new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIMs) and their major subgroups.
Methods: An international, multidisciplinary group of myositis experts produced a set of 93 potentially relevant variables to be tested for inclusion in the criteria. Rheumatology, dermatology, neurology and paediatric clinics worldwide collected data on 976 IIM cases (74% adults, 26% children) and 624 non-IIM comparator cases with mimicking conditions (82% adults, 18% children). The participating clinicians classified each case as IIM or non-IIM. Generally, the classification of any given patient was based on few variables, leaving remaining variables unmeasured. We investigated the strength of the association between all variables and between these and the disease status as determined by the physician. We considered three approaches: (1) a probability-score approach, (2) a sum-of-items approach criteria and (3) a classification-tree approach.
Results: The approaches yielded several candidate models that were scrutinised with respect to statistical performance and clinical relevance. The probability-score approach showed superior statistical performance and clinical practicability and was therefore preferred over the others. We developed a classification tree for subclassification of patients with IIM. A calculator for electronic devices, such as computers and smartphones, facilitates the use of the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria.
Conclusions: The new EULAR/ACR classification criteria provide a patient's probability of having IIM for use in clinical and research settings. The probability is based on a score obtained by summing the weights associated with a set of criteria items.
Keywords: autoimmune diseases; dermatomyositis; polymyositis.
Conflict of interest statement
Competing interests: JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Bioiberica, Crealta and Allergan. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. HC and RGC’s work in myositis is partly funded by grants from Arthritis Research UK (18474) and the Medical Research Council (MR/N003322/1). JV’s work in myositis is supported by the Project (Ministry of Health, Czech Republic) for Conceptual Development of Research Organization 00023728.
Figures
Similar articles
-
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.Ann Rheum Dis. 2017 Dec;76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468. Epub 2017 Oct 27. Ann Rheum Dis. 2017. PMID: 29079590 Free PMC article.
-
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Arthritis Rheumatol. 2017. PMID: 29106061 Free PMC article.
-
Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort.Semin Arthritis Rheum. 2020 Jun;50(3):492-497. doi: 10.1016/j.semarthrit.2019.12.001. Epub 2019 Dec 28. Semin Arthritis Rheum. 2020. PMID: 32024593
-
First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort.Ann Rheum Dis. 2020 Mar;79(3):387-392. doi: 10.1136/annrheumdis-2019-215488. Epub 2019 Nov 6. Ann Rheum Dis. 2020. PMID: 31694813
-
Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review.Clin Exp Rheumatol. 2024 Feb;42(2):403-412. doi: 10.55563/clinexprheumatol/vuc5py. Epub 2024 Feb 28. Clin Exp Rheumatol. 2024. PMID: 38436279 Review.
Cited by
-
Comparison of characteristics and anti-MDA5 antibody distribution and effect between clinically amyopathic dermatomyositis and classic dermatomyositis: a retrospective case-control study.Front Immunol. 2023 Nov 27;14:1237209. doi: 10.3389/fimmu.2023.1237209. eCollection 2023. Front Immunol. 2023. PMID: 38098481 Free PMC article.
-
Sarcoplasmic Myxovirus Resistance Protein A: A Study of Expression in Idiopathic Inflammatory Myopathy.J Inflamm Res. 2023 Nov 20;16:5417-5426. doi: 10.2147/JIR.S433239. eCollection 2023. J Inflamm Res. 2023. PMID: 38026261 Free PMC article.
-
Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.Clin Rheumatol. 2023 Dec;42(12):3289-3297. doi: 10.1007/s10067-023-06751-0. Epub 2023 Oct 6. Clin Rheumatol. 2023. PMID: 37801141
-
Antisynthetase Syndrome: The Classical Phenotype With a Twist.Cureus. 2023 Jul 24;15(7):e42360. doi: 10.7759/cureus.42360. eCollection 2023 Jul. Cureus. 2023. PMID: 37621814 Free PMC article.
-
Fever in the initial stage of IIM patients: an early clinical warning sign for AE-ILD.Adv Rheumatol. 2023 Jul 13;63(1):31. doi: 10.1186/s42358-023-00313-3. Adv Rheumatol. 2023. PMID: 37443073
References
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources